EuroPCR Establishes Nobles Medical Technologies II As The Potential Leader In The Rapidly Growing PFO Closure Market
Nobles Medical Technologies II Experienced Its Largest Customer Response of Physicians From Around The World Attending EuroPCR Requesting To Be Trained To Provide NobleStitch To Their Patients, Many Of Which Requested The NobleStitch Directly
PARIS, May 31, 2018 /PRNewswire/ -- Nobles Medical Technologies II, Inc. (NMT 2) today announced that following a highly successful showing at EuroPCR of the NobleStitch, the company will accelerate its sales, marketing and proctoring efforts to meet the increased demand in both existing countries and new territories. The company noted receiving un-paralleled interest in its NobleStitch™ EL suture-based PFO closure system. Supported by the recently published data in EuroIntervention, and a live presentation of the Italian data by Dr. Frederico De Marco of Milan's Policlinico San Donato Hospital. The findings presented ushered a large wave of interested Physicians and distributors to the Company's booth and provided an opportunity for direct discussions with Professor Anthony Nobles, CEO as well as several of the key investigators such as Prof Achille Gaspardone and Dr. Frederico De Marco, who provided direct feedback on their experience of over 100 NobleStitch cases.
Nobles Medical also announced during the EuroPCR congress that it had recently completed 1000 NobleStitch™ cases, without a single device related complication and without a single atrial fibrillation, a common problem with occlude based implants. This milestone establishes the NobleStitch™ EL as a legitimate competitor in the rapidly growing PFO Closure market. The Company also announce the launch of the next generation NobleStitch™ which received enthusiastic accolades from its current customers that attended the conference as well as the vast number of new customers interested to start their training with the NobleStitch™ EL 2.
Dr. Achille Gaspardone, Director of Cardiology at Hospital of Sant'Eugenio (Rome, Italy), stated, "I was personally excited to have the opportunity to visit the NobleStitch booth and see a never-ending stream of my colleagues that converged on HeartStitch exhibit. I was asked by my fellow interventional cardiologists about my experience and my data and I explained that the NobleStitch™ EL is the first choice for PFO Closure and that the data that we recently published demonstrates the superior safety profile of this incredible technology. It was exciting to be asked to come and proctor at several hospitals from Switzerland to Spain, of which I have already scheduled to share my knowledge and experience with the centers that clearly see the benefit of the NobleStitch™ for their patients."
Professor Anthony Nobles, remarked, "In my over 30 years in the medical device business both presenting and lecturing at major congresses, I have never had a product that generated such excitement, I was overwhelmed with the response that we received for the NobleStitch™ EL at this year's EuroPCR. Our current physicians using the product are very vocal that this is their first choice for PFO closure. It was incredible to watch our key opinion leaders spontaneously engage their colleagues with excitement to share their experience and conviction for our product, and the benefits it provides for their patients. Distributors from around the globe were escorting their doctors to us to have a one on one demonstration."
Read more details about the Italian Registry report utilizing the NobleStitch™ EL:
(https://www.prnewswire.com/news-releases/noblestitch-el-italian-registry-data-published-in-eurointervention-300626377.html).
About Nobles Medical Technology II
Nobles Medical Technology II, Inc. was founded by Prof. Anthony Nobles with the intent of leveraging its technologies in the cardiovascular-suturing marketplace. The company does business under the name of Nobles Medical II (NMT II).
The NobleStitch™ EL is FDA cleared for Vascular and Cardiovascular suturing in the United States. Further information including warnings and precautions can be found in the instructions for use.
NobleStitch™ EL is distributed worldwide by HeartStitch®, Inc. (HeartStitch® is a registered trademark of HeartStitch, Inc.).
NobleStitch™ EL
Covered by or for use under U.S. and international patents including one or more of U.S. Patent Nos. 5860990, 6117144, 6245079, 6551331, 6562052, 6733509, 7004952, 7090686, 7803167, 8197497, 8197510, 8246636, 8348962, 8372089, 8469975, 8496676, 8709020, and 9131938.
For more on Nobles Medical Technologies II visit
SOURCE Nobles Medical Technologies II, Inc.
Share this article